ADMA Biologics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ADMA Biologics generated cash of $8,800,000, which is more than the previous year. Cash used in financing activities reached the amount of -$38,989,000 last year. Net change in cash is therefore -$35,170,000.
Cash Flow
| 2014 | -14.70M | -4.04M | 9.79M |
|---|---|---|---|
| 2015 | -15.41M | -1.74M | 10.40M |
| 2016 | -18.26M | 904.58K | 16.83M |
| 2017 | -37.27M | 15.21M | 60.75M |
| 2018 | -62.67M | -2.09M | 42.92M |
| 2019 | -76.19M | -3.81M | 80.00M |
| 2020 | -102.00M | -12.72M | 143.89M |
| 2021 | -112.36M | -13.51M | 121.04M |
| 2022 | -59.50M | -13.91M | 108.85M |
| 2023 | 8.8M | -4.98M | -38.98M |
ADMA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 86.52M | 51.08M | 55.92M | 26.75M | 26.75M | 48.60M | 9.91M | 10.44M | 17.19M | 26.14M |
Operating activities | ||||||||||
Net income | -28.23M | -65.90M | -71.64M | -75.74M | -48.27M | -65.74M | -43.75M | -19.51M | -17.96M | -16.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 8.33M | 7.11M | 5.49M | 3.94M | 3.25M | 3.44M | 2.69M | 469.57K | 469.82K | 247.85K |
Stock-based compensation expense | 6.18M | 5.21M | 3.48M | 2.85M | 2.65M | 0 | 1.56M | 1.25M | 1.71M | 1.24M |
| Deferred income tax benefit | 6.18M | 5.21M | 3.48M | 2.85M | 2.65M | 0 | 1.56M | 1.25M | 1.71M | 1.24M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -11.91M | 13.07M | -15.33M | -9.76M | -2.07M | 2.48M | -2.86M | -93.55K | -540.50K | -383.96K |
Inventories | -9.62M | -38.55M | -43.18M | -28.47M | -34.65M | -5.98M | 589.31K | -1.57M | -1.73M | -39.70K |
Accounts payable | 3.83M | 799.98K | 1.35M | 1.89M | 3.27M | -20.48K | 2.81M | 476.82K | 308.65K | -937.77K |
Cash generated by operating activities | 8.8M | -59.50M | -112.36M | -102.00M | -76.19M | -62.67M | -37.27M | -18.26M | -15.41M | -14.70M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -12.5M | -15.68M | -1.71M | -1.71M |
Investments In Property Plant And Equipment | -4.77M | -13.91M | -13.51M | -12.72M | -3.81M | -2.09M | -2.67M | -73.41K | -26.07K | -2.32M |
Acquisitions Net | 0 | 0 | 0 | 2K | 0 | 0 | 12.5M | 0 | 0 | 0 |
Cash generated by investing activities | -4.98M | -13.91M | -13.51M | -12.72M | -3.81M | -2.09M | 15.21M | 904.58K | -1.74M | -4.04M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 64.64M | 121.14M | 131.19M | 48.39M | 0 | 39.19M | 14.14M | 10.25M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.41M | 0 | -61.59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -23.60M | 51.71M | -34.29K | -13.98M | 42.47M | -36.27K | 24.98M | -15.13K | 685.37K | -12.65K |
Cash used in financing activities | -38.98M | 108.85M | 121.04M | 143.89M | 80.00M | 42.92M | 60.75M | 16.83M | 10.40M | 9.79M |
Net Change In Cash | -35.17M | 35.43M | -4.83M | 29.16M | -2.71K | -21.85M | 38.69M | -526.09K | -6.75M | -8.95M |
Cash at end of period | 51.35M | 86.52M | 51.08M | 55.92M | 26.75M | 26.75M | 48.60M | 9.91M | 10.44M | 17.19M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |